Antibiotics (UTI - enrofloxacin, TMS)

Urinary tract infections represent one of the most common bacterial conditions affecting small mammals, requiring prompt and appropriate antibiotic therapy to prevent serious complications including ascending infections that can damage the kidneys. Enrofloxacin and trimethoprim-sulfamethoxazole (TMS) stand as the two primary antibiotic choices for treating urinary tract infections in exotic small mammals because both medications are considered safe for the unique gastrointestinal flora of these sensitive species. Unlike many antibiotics that can cause fatal dysbiosis in hindgut fermenters, these two antibiotic classes can be administered orally without the catastrophic disruption to beneficial gut bacteria that makes beta-lactam antibiotics deadly to guinea pigs, chinchillas, hamsters, and rabbits.

Enrofloxacin belongs to the fluoroquinolone class of antibiotics and works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. This mechanism of action makes enrofloxacin bactericidal against a broad spectrum of gram-negative and some gram-positive organisms commonly responsible for urinary tract infections. The drug achieves excellent tissue penetration and concentrates well in urinary tissues, making it particularly effective for treating infections of the bladder, ureters, and kidneys. Trimethoprim-sulfamethoxazole works through a synergistic dual mechanism that blocks sequential steps in bacterial folic acid synthesis, creating a bactericidal effect when the two components are combined.

Both antibiotics have been used extensively in veterinary medicine for decades, with enrofloxacin originally developed for veterinary applications before human fluoroquinolones became widely available. The veterinary formulations are well-documented for use in companion animals, though most applications in small exotic mammals represent extra-label use that requires veterinary oversight and species-appropriate dosing. Commercial preparations include injectable solutions and oral formulations, though many small mammal patients require compounded preparations to achieve appropriate concentrations for their diminutive body sizes and to improve palatability for owner-administered treatments.

The safety profile of these antibiotics in small mammals distinguishes them from the many antibiotic classes that pose severe risks to hindgut-fermenting species. While fluoroquinolones carry some species-specific concerns regarding cartilage development in young animals and potential for causing gastrointestinal upset, they do not cause the fatal overgrowth of Clostridium species and other pathogenic bacteria that makes beta-lactams, lincosamides, and macrolides dangerous to rabbits and rodents. Similarly, trimethoprim-sulfa combinations are well-tolerated by small mammal gastrointestinal systems and can be safely administered orally for extended treatment courses necessary to fully resolve urinary tract infections.

The primary indication for enrofloxacin and trimethoprim-sulfamethoxazole in small mammals is the treatment of bacterial urinary tract infections affecting the bladder, urethra, ureters, or kidneys. Lower urinary tract infections, commonly called cystitis, represent the most frequent presentation and typically manifest with clinical signs including blood in the urine, frequent urination attempts, straining to urinate, vocalization during urination, and urine scalding of the perineal area. Upper urinary tract infections involving the kidneys present more seriously with systemic signs of illness including lethargy, decreased appetite, fever, and potential for life-threatening sepsis if left untreated.

Guinea pigs are particularly prone to urinary tract infections and bladder stones, with female guinea pigs showing higher incidence due to their shorter urethras and proximity of the urethral opening to the anus. These infections often occur secondary to poor husbandry, inadequate water intake, or the presence of urinary calculi that irritate the bladder lining and provide a nidus for bacterial colonization. Rabbits similarly develop urinary tract infections, frequently associated with their unique calcium metabolism that produces normally thick, calcium-rich urine predisposing them to sludge accumulation and bacterial overgrowth. Both species benefit from prompt antibiotic therapy combined with supportive care and correction of underlying husbandry issues.

Ferrets develop urinary tract infections less commonly than herbivorous small mammals but may require antibiotic therapy when infections occur, particularly in animals with underlying conditions such as adrenal disease affecting the prostate in males or those with urinary obstruction requiring catheterization. Hamsters, gerbils, rats, and mice can all develop urinary infections, though diagnosis may be more challenging in these smaller species due to difficulty obtaining clean urine samples. Hedgehogs and sugar gliders occasionally present with urinary tract infections requiring appropriate antibiotic selection from the limited options safe for these species.

Beyond primary urinary tract infections, these antibiotics may be prescribed for secondary infections associated with urinary calculi before and after surgical stone removal, infections following urinary catheterization or other procedures involving the urinary tract, and prophylactically in some cases where procedures carry high infection risk. The broad-spectrum activity of enrofloxacin makes it useful when culture and sensitivity results are pending or unavailable, while trimethoprim-sulfa provides an alternative when fluoroquinolones are contraindicated or when bacterial sensitivity patterns favor sulfonamide therapy.

Extra-label uses of these antibiotics extend beyond the urinary tract in small mammals, with enrofloxacin frequently prescribed for respiratory infections, skin infections, dental abscesses, and other bacterial conditions where gram-negative coverage is required. Trimethoprim-sulfa similarly finds application in respiratory disease, skin infections, and certain protozoal conditions. However, when treating urinary tract infections specifically, these medications are selected for their excellent urinary tissue penetration, appropriate spectrum of activity against common urinary pathogens, and critical safety for the sensitive gastrointestinal systems of small herbivorous and omnivorous mammals.

Dosing of antibiotics for urinary tract infections in small mammals requires careful consideration of the dramatic differences in body size, metabolism, and pharmacokinetics among the diverse species grouped under this category. A guinea pig may weigh one kilogram while a mouse weighs thirty grams, requiring vastly different absolute doses despite similar weight-based calculations. Exotic veterinarians experienced with small mammal medicine must determine appropriate dosing for each individual patient, taking into account species-specific metabolism, severity of infection, patient health status, and the specific antibiotic formulation being used. Pet owners should never attempt to dose these medications without veterinary guidance, as both underdosing leading to treatment failure and overdosing causing toxicity represent serious risks.

Enrofloxacin is typically administered once or twice daily depending on species metabolism and veterinary preference, with most small mammals receiving oral preparations for owner administration at home following initial veterinary assessment. The injectable formulation may be used for initial treatment in severely ill patients or those unable to accept oral medication, with transition to oral therapy once the patient stabilizes. Oral enrofloxacin is available in various concentrations, and compounding pharmacies frequently prepare species-appropriate suspensions in palatable flavors to facilitate administration. The medication is often given diluted or followed by water or food to reduce the risk of oral irritation that can occur with concentrated fluoroquinolone solutions.

Trimethoprim-sulfamethoxazole is similarly administered orally once or twice daily, with injectable formulations available for veterinary use in hospitalized patients. The oral suspension is often better accepted than enrofloxacin due to its more neutral taste, though compounding into flavored preparations further improves compliance. The combination nature of this medication provides synergistic antibacterial activity, making it effective against many urinary pathogens while maintaining the safety profile necessary for small mammal gastrointestinal health. Duration of therapy typically extends for two to four weeks for uncomplicated urinary tract infections, with some cases requiring longer treatment courses.

Administration technique significantly impacts treatment success in small mammals, as stress from handling can worsen clinical condition and fighting during medication administration can result in aspiration or injury. Small syringe feeding techniques allow precise measurement and controlled delivery of oral medications directly into the mouth while minimizing stress. Many experienced owners and veterinary staff recommend wrapping the animal gently in a towel for restraint, supporting the body securely while leaving the head accessible for medication delivery. Slow, gentle administration allows the animal to swallow naturally rather than forcing large volumes that may be aspirated or spit out.

Compounding requirements for small mammal patients cannot be overstated, as commercial antibiotic preparations are manufactured for much larger patients and may be impossible to dose accurately for animals weighing less than one hundred grams. Reputable veterinary compounding pharmacies prepare concentrated suspensions, flavored formulations, and precisely measured preparations that allow accurate dosing for even the smallest patients. These compounded medications have limited stability compared to commercial products, requiring proper refrigeration and use within specified timeframes. The veterinarian prescribing the antibiotic will provide specific storage and administration instructions for the compounded preparation.

Monitoring during antibiotic therapy helps ensure treatment success and allows early detection of adverse effects. Owners should observe appetite, activity level, fecal output, and urination patterns throughout the treatment course, reporting any changes to the prescribing veterinarian. Follow-up urinalysis and possibly urine culture after completing the antibiotic course confirms resolution of infection and guides decisions about discontinuing therapy versus extending treatment. Some chronic or complicated urinary tract infections require extended therapy lasting weeks to months, necessitating periodic monitoring for antibiotic-related adverse effects alongside assessment of infection status.

Both enrofloxacin and trimethoprim-sulfamethoxazole are generally well-tolerated by small mammals when administered at appropriate doses, but adverse effects can occur and owners should monitor their pets throughout treatment. Gastrointestinal disturbances represent the most common side effects, manifesting as decreased appetite, soft stools, or mild diarrhea. Unlike the fatal dysbiosis caused by beta-lactam and certain other antibiotics in hindgut fermenters, the gastrointestinal effects of these safe antibiotics are typically mild and self-limiting. However, any significant decrease in food intake, cessation of fecal output, or signs of abdominal discomfort warrant immediate veterinary attention as small mammals can deteriorate rapidly when not eating.

Enrofloxacin carries specific concerns regarding cartilage damage in young, growing animals, as fluoroquinolones can affect developing joint cartilage and potentially cause lameness or joint abnormalities. This effect is best documented in dogs but likely occurs across mammalian species, leading most veterinarians to avoid fluoroquinolones in very young animals or to use them only when clearly necessary and no suitable alternatives exist. Mature animals with fully developed skeletal systems do not face this same risk, making enrofloxacin appropriate for adult small mammals requiring urinary tract infection treatment. Oral irritation and esophageal damage can occur if concentrated enrofloxacin solutions contact oral tissues for prolonged periods, emphasizing the importance of appropriate dilution and followed administration with water or food.

Trimethoprim-sulfamethoxazole can occasionally cause hypersensitivity reactions in sensitive individuals, though this is uncommon in small mammals. Signs of hypersensitivity might include facial swelling, hives, breathing difficulty, or sudden collapse requiring immediate veterinary intervention. Bone marrow suppression represents a rare but serious potential adverse effect of sulfonamide antibiotics with prolonged use, potentially affecting red blood cell, white blood cell, or platelet production. Extended treatment courses should include periodic monitoring for signs of anemia, increased infection susceptibility, or bleeding tendencies. Crystalluria, the precipitation of sulfonamide crystals in urine, can theoretically occur with inadequate water intake during treatment, making hydration support particularly important for patients receiving this medication.

Species-specific adverse effects include potential vitamin K deficiency with prolonged trimethoprim-sulfa therapy in animals with compromised gut flora or inadequate dietary vitamin K intake. Guinea pigs may be particularly susceptible given their vitamin C requirements and coprophagy-dependent nutrient acquisition. Neurological signs including seizures have been rarely reported with fluoroquinolone toxicity, typically associated with overdosing or use in animals with underlying neurological conditions. Gerbils have inherent seizure susceptibility and may theoretically have enhanced risk of fluoroquinolone-associated neurological effects, though clinical documentation of this specific concern is limited.

Owners should monitor their small mammals daily during antibiotic treatment, observing for normal appetite and food consumption, typical fecal output in terms of quantity and consistency, normal urination patterns, maintenance of normal activity level and behavior, and absence of signs of pain, discomfort, or distress. Any significant changes from baseline should prompt consultation with the prescribing veterinarian, who can determine whether adjustment of therapy is warranted. Most adverse effects resolve with discontinuation of the offending medication, though supportive care may be necessary for animals experiencing significant gastrointestinal disturbance or other complications.

Absolute contraindications for enrofloxacin and trimethoprim-sulfamethoxazole are relatively limited compared to the many antibiotics that cannot be safely used in small mammals, but certain situations preclude use of these medications or require careful risk-benefit analysis. Known hypersensitivity to fluoroquinolones or sulfonamide antibiotics represents an absolute contraindication, as re-exposure can trigger severe allergic reactions including anaphylaxis. Animals with documented previous adverse reactions to these drug classes should receive alternative antibiotics selected by their veterinarian based on culture and sensitivity results or empirical alternatives with different mechanisms of action.

Enrofloxacin should be avoided or used with extreme caution in young, growing animals due to the risk of cartilage damage affecting joint development. The age threshold varies by species, but generally animals still in active growth phases face the greatest risk. Pregnant animals represent another population where fluoroquinolones should be avoided when possible, as these drugs cross the placenta and the effects on fetal cartilage development mirror those seen in young animals. Nursing mothers can transfer fluoroquinolones to offspring through milk, extending the same concerns to the nursing period. When urinary tract infection treatment is essential during pregnancy or lactation, trimethoprim-sulfa may be preferred, though this medication also carries some reproductive concerns and should be used only when clearly necessary.

Trimethoprim-sulfamethoxazole carries contraindications related to its potential for bone marrow suppression and should be avoided in animals with pre-existing blood dyscrasias, documented bone marrow disorders, or concurrent use of other medications known to affect bone marrow function. Severe hepatic impairment may affect metabolism of both drug components, potentially leading to accumulation and increased toxicity risk. Renal impairment presents complex considerations since the urinary tract infection requiring treatment may itself be affecting kidney function, but severe renal disease can impair excretion of these antibiotics and may require dose adjustment or selection of alternative therapy.

Dehydrated patients should have fluid status corrected before or concurrent with initiating sulfonamide therapy to reduce the risk of crystalluria and potential renal tubular damage from precipitated drug crystals. Animals unable or unwilling to drink adequate water during treatment may require fluid supplementation to maintain appropriate hydration. Certain drug interactions create relative contraindications, including concurrent use of medications that prolong QT interval with fluoroquinolones or other antifolate medications with trimethoprim-sulfa that could produce additive bone marrow effects. The prescribing veterinarian must review all current medications and health conditions before selecting antibiotic therapy for urinary tract infection treatment.

Drug interactions with enrofloxacin and trimethoprim-sulfamethoxazole require consideration when small mammal patients receive concurrent medications for other health conditions or supportive care during urinary tract infection treatment. Enrofloxacin absorption can be significantly reduced by concurrent administration of medications or supplements containing divalent or trivalent cations, including calcium, magnesium, aluminum, iron, and zinc. Antacids, calcium supplements, and mineral-containing products should be administered several hours apart from enrofloxacin doses to avoid chelation of the antibiotic in the gastrointestinal tract that reduces its bioavailability. This interaction is particularly relevant for guinea pigs that may receive calcium supplementation or for any small mammal receiving mineral-containing supportive care.

Theophylline and related methylxanthine bronchodilators can have their metabolism inhibited by fluoroquinolones, potentially leading to elevated drug levels and toxicity. Small mammals with respiratory conditions receiving theophylline may require dose adjustment or enhanced monitoring when enrofloxacin therapy is initiated. Nonsteroidal anti-inflammatory drugs combined with fluoroquinolones may theoretically increase the risk of central nervous system stimulation and seizures, a consideration for patients receiving pain management alongside antibiotic therapy. This interaction appears more significant in some species than others but warrants awareness when treating small mammals with both drug classes.

Trimethoprim-sulfamethoxazole interactions include potentiation of oral anticoagulant effects through displacement from protein binding sites and inhibition of metabolism, though anticoagulant use in small mammals is uncommon. The antifolate mechanism of trimethoprim can interact with other medications affecting folate metabolism, including methotrexate and pyrimethamine, potentially producing additive bone marrow suppression. Concurrent use of other medications with bone marrow suppressive potential should be approached cautiously with careful monitoring for hematological adverse effects. Certain diuretics including thiazides may have enhanced effects when combined with sulfonamides, and potassium-sparing diuretics combined with trimethoprim can rarely produce significant hyperkalemia.

Beneficial drug interactions may be exploited therapeutically, such as the synergistic antibacterial effects achieved by combining different antibiotic classes when treating severe or resistant infections. However, such combination therapy requires veterinary expertise to ensure appropriate selection of compatible medications at safe doses. The potential for interaction with probiotics and gastrointestinal support products used to maintain gut flora health during antibiotic therapy is generally minimal with these safe antibiotic classes, allowing concurrent use of supportive care products that help maintain normal intestinal bacterial populations. Owners should always inform their veterinarian of all medications, supplements, and supportive care products their small mammal receives to allow comprehensive drug interaction assessment.

While enrofloxacin and trimethoprim-sulfamethoxazole are considered safe antibiotics for small mammals compared to the many antibiotics that cause fatal dysbiosis, appropriate precautions maximize treatment safety and efficacy. These medications should only be used under veterinary supervision, with proper diagnosis confirming bacterial urinary tract infection before initiating antibiotic therapy. Empirical treatment without diagnostic confirmation can mask other conditions, promote antibiotic resistance, and subject patients to unnecessary medication risks. Urinalysis, and ideally urine culture with sensitivity testing, guides appropriate antibiotic selection and helps ensure the chosen medication will effectively treat the specific pathogen involved.

The critical importance of maintaining adequate hydration during urinary tract infection treatment cannot be overstated, particularly for patients receiving sulfonamide antibiotics where dehydration can contribute to crystalluria. Small mammals may reduce water intake when feeling unwell, and species like chinchillas and guinea pigs can quickly become dehydrated without obvious clinical signs until severely affected. Owners should monitor water consumption, provide fresh water in clean containers appropriate for the species, and consider offering water-rich vegetables or syringe-feeding water supplements if intake appears reduced. Subcutaneous fluid administration by the veterinarian may be necessary for patients with inadequate oral intake.

Monitoring for adverse effects throughout the treatment course allows early intervention if problems develop. Owners should observe daily food intake, fecal output, urination patterns, and general demeanor, reporting significant changes to the prescribing veterinarian. Gastrointestinal slowdown in hindgut-fermenting species like guinea pigs, chinchillas, and rabbits can rapidly progress to life-threatening gastrointestinal stasis and should prompt immediate veterinary attention. While these safe antibiotics rarely cause such severe gastrointestinal effects, any small mammal can experience individual adverse reactions requiring treatment modification.

Complete the full prescribed course of antibiotic therapy even if clinical signs appear to resolve before the medication is finished. Premature discontinuation of antibiotics allows surviving bacteria to repopulate, potentially with acquired resistance that makes subsequent treatment more difficult. Urinary tract infections can persist in deeper tissues even when superficial signs resolve, and inadequate treatment duration allows deep-seated infection to recrudesce. Follow-up urinalysis after completing treatment confirms infection resolution and identifies cases requiring extended therapy. Owners who cannot complete the full treatment course for any reason should contact their veterinarian rather than simply stopping medication.

Human safety considerations apply when handling these medications, as both enrofloxacin and sulfonamides can cause adverse reactions in sensitive individuals. People with known allergies to fluoroquinolones or sulfa drugs should avoid direct contact with these medications and may need to arrange for another family member to administer treatments. Pregnant women should exercise caution when handling any medications due to potential effects on fetal development. Proper handwashing after medication administration and avoiding contact with eyes or mucous membranes minimizes human exposure risk. Medications should be stored securely away from children and other pets, and unused medications should be disposed of properly according to local guidelines or through veterinary take-back programs.

Proper storage of enrofloxacin and trimethoprim-sulfamethoxazole maintains medication stability and ensures therapeutic effectiveness throughout the treatment course. Commercial preparations have specific storage requirements listed on their packaging that should be followed precisely, with most oral formulations requiring storage at controlled room temperature away from excessive heat, light, and moisture. Injectable formulations may have different requirements including refrigeration, and should be stored according to manufacturer specifications. Medications exposed to improper storage conditions may degrade, losing potency or developing harmful breakdown products that could affect patient safety.

Compounded preparations for small mammal patients typically have shorter stability periods than commercial formulations and often require refrigeration to maintain potency throughout the prescribed treatment course. The compounding pharmacy will provide specific storage instructions, expiration dating, and any special handling requirements for the customized preparation. These instructions must be followed carefully, as compounded medications may lose effectiveness or become unstable more quickly than commercially manufactured products. Discard any remaining medication after the compounded preparation's expiration date rather than saving it for potential future use, as degraded medication may be ineffective or harmful.

Handling precautions protect both the medication and the people administering it. Keep medications in their original containers with labels intact to prevent confusion about drug identity, concentration, and dosing instructions. Use clean syringes or measuring devices for each administration to prevent contamination that could affect medication stability or introduce bacteria into the preparation. Oral syringes used for medication administration should be rinsed with clean water between doses and replaced if they become damaged, discolored, or difficult to read. Store medications securely out of reach of children and other household pets, as accidental ingestion of concentrated antibiotic preparations could cause serious adverse effects in unintended recipients.

Guinea pigs and chinchillas share similar antibiotic safety concerns as hindgut-fermenting herbivores with complex gastrointestinal microbiomes essential for health and survival. Both species can safely receive enrofloxacin and trimethoprim-sulfamethoxazole for urinary tract infections, with these antibiotics representing first-line choices when empirical treatment is necessary before culture results become available. Guinea pigs are particularly prone to urinary tract infections and bladder stones, often requiring combined medical and potentially surgical management. Their vitamin C requirements should be maintained during illness, as stress and anorexia can rapidly deplete vitamin C stores. Chinchillas require careful attention to environmental temperature during treatment, as heat stress can worsen clinical condition and complicate recovery from urinary tract infection.

Rabbits similarly tolerate fluoroquinolones and sulfonamides well despite their sensitive hindgut fermentation, making these antibiotics appropriate choices for treating the urinary tract infections that commonly affect this species. Rabbit urinary physiology differs from other mammals in producing normally cloudy, calcium-rich urine that can predispose to sludge accumulation and secondary bacterial infection. Treatment of rabbit urinary tract infections often requires attention to underlying husbandry factors including diet composition, water intake, and exercise that affect urinary health. Long-term management may require dietary modification to reduce calcium intake alongside acute antibiotic therapy for active infection.

Ferrets have fundamentally different gastrointestinal physiology than hindgut-fermenting small mammals and can safely receive the beta-lactam antibiotics that would be fatal to rabbits and rodents. However, enrofloxacin and trimethoprim-sulfamethoxazole remain appropriate choices for ferret urinary tract infections and may be preferred based on culture and sensitivity results or veterinary experience. Ferrets may develop urinary tract infections secondary to prostatic disease associated with adrenal tumors, with treatment addressing both the infection and the underlying endocrine disorder. Male ferrets with adrenal disease may require catheterization for urinary obstruction, with prophylactic or therapeutic antibiotics indicated to prevent or treat catheter-associated infection.

Smaller rodent species including hamsters, gerbils, rats, and mice present challenges related to their diminutive size requiring precisely compounded medications and careful attention to dosing accuracy. These species generally tolerate enrofloxacin and trimethoprim-sulfamethoxazole safely, though the stress of handling for medication administration may impact recovery. Rats and mice are commonly used in research settings where extensive pharmacokinetic data exists, while hamster and gerbil treatment often relies on extrapolation from better-studied species. Gerbils have inherent seizure susceptibility that warrants awareness when using any medication, though clinically significant fluoroquinolone-associated seizures appear rare at appropriate therapeutic doses. Hedgehogs and sugar gliders represent less commonly kept species where limited species-specific data guides antibiotic selection, with these safe antibiotic classes generally preferred over those with documented dysbiosis risk in other exotic species.

Alternative fluoroquinolone antibiotics to enrofloxacin include marbofloxacin and ciprofloxacin, which share the same mechanism of action and similar spectrum of activity against gram-negative urinary pathogens. Marbofloxacin offers once-daily dosing in some species and may be preferred by some veterinarians for specific clinical situations. Ciprofloxacin is the human formulation most closely related to enrofloxacin and may occasionally be prescribed when veterinary fluoroquinolones are unavailable, though the pharmacokinetics differ between species and require appropriate dose adjustment. All fluoroquinolones share the safety profile that makes this class appropriate for hindgut-fermenting small mammals while also sharing the cartilage development concerns that limit use in young animals.

Other safe antibiotics for small mammals that may be selected for urinary tract infection treatment include chloramphenicol, which provides broad-spectrum coverage including many urinary pathogens, and doxycycline, which concentrates well in urinary tissues. These alternatives may be chosen based on culture and sensitivity results, patient factors that contraindicate first-line choices, or veterinary preference and experience. Metronidazole offers activity against anaerobic bacteria and certain protozoa but has limited utility as monotherapy for typical urinary tract infections caused by aerobic gram-negative organisms. Azithromycin provides another macrolide option that is generally safe for small mammals, though its spectrum of activity may not optimally match common urinary pathogens.

Supportive care medications often accompany antibiotic therapy for urinary tract infection treatment, including analgesics for pain management, anti-inflammatory medications to reduce bladder inflammation, and prokinetics or appetite stimulants to maintain gastrointestinal function during illness and treatment. Fluid therapy represents the most important supportive intervention for many urinary tract infection patients, helping to flush bacteria from the urinary tract while maintaining hydration essential for sulfonamide safety. Probiotics and prebiotic supplements may help maintain beneficial gut flora during antibiotic treatment, though their efficacy is better established for some species than others. The veterinarian managing the case will select appropriate supportive care based on individual patient needs and clinical presentation.